CA2889109C - Composition comprising citrulline and citicoline for improving decline in brain function - Google Patents

Composition comprising citrulline and citicoline for improving decline in brain function Download PDF

Info

Publication number
CA2889109C
CA2889109C CA2889109A CA2889109A CA2889109C CA 2889109 C CA2889109 C CA 2889109C CA 2889109 A CA2889109 A CA 2889109A CA 2889109 A CA2889109 A CA 2889109A CA 2889109 C CA2889109 C CA 2889109C
Authority
CA
Canada
Prior art keywords
decreased
salt
citrulline
ability
citicoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2889109A
Other languages
English (en)
French (fr)
Other versions
CA2889109A1 (en
Inventor
Kota KUMAGAI
Masahiko Morita
Takahiro Hara
Kohji FUKUNAGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of CA2889109A1 publication Critical patent/CA2889109A1/en
Application granted granted Critical
Publication of CA2889109C publication Critical patent/CA2889109C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2889109A 2012-10-30 2013-10-30 Composition comprising citrulline and citicoline for improving decline in brain function Active CA2889109C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012238542 2012-10-30
JP2012-238542 2012-10-30
PCT/JP2013/080053 WO2014069667A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (2)

Publication Number Publication Date
CA2889109A1 CA2889109A1 (en) 2014-05-08
CA2889109C true CA2889109C (en) 2020-09-01

Family

ID=50627559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2889109A Active CA2889109C (en) 2012-10-30 2013-10-30 Composition comprising citrulline and citicoline for improving decline in brain function

Country Status (9)

Country Link
US (2) US10905705B2 (enExample)
EP (1) EP2914270B1 (enExample)
JP (1) JP6166786B2 (enExample)
AU (1) AU2013339058B2 (enExample)
CA (1) CA2889109C (enExample)
ES (1) ES2906614T3 (enExample)
NZ (1) NZ707081A (enExample)
PL (1) PL2914270T3 (enExample)
WO (1) WO2014069667A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function
CN117069780A (zh) 2016-10-06 2023-11-17 协和发酵生化株式会社 胞苷二磷酸胆碱的晶体及其制造方法
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤
JP2019218284A (ja) * 2018-06-18 2019-12-26 オンガネジャパン株式会社 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法
WO2025258678A1 (ja) * 2024-06-13 2025-12-18 キリンホールディングス株式会社 神経回路の興奮を促進するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213000A1 (en) * 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP5931325B2 (ja) * 2008-01-30 2016-06-08 協和発酵バイオ株式会社 注意集中力向上剤
CN102316852A (zh) * 2009-02-11 2012-01-11 丽卡实验有限公司 脂质胞二磷胆碱注射液
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Also Published As

Publication number Publication date
AU2013339058B2 (en) 2017-09-07
EP2914270A4 (en) 2016-03-16
WO2014069667A1 (en) 2014-05-08
US20150306125A1 (en) 2015-10-29
AU2013339058A1 (en) 2015-05-07
US20210113601A1 (en) 2021-04-22
US11738037B2 (en) 2023-08-29
EP2914270A1 (en) 2015-09-09
US10905705B2 (en) 2021-02-02
EP2914270B1 (en) 2022-01-12
JP2015535241A (ja) 2015-12-10
PL2914270T3 (pl) 2022-03-14
ES2906614T3 (es) 2022-04-19
CA2889109A1 (en) 2014-05-08
NZ707081A (en) 2019-03-29
JP6166786B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
US11738037B2 (en) Agent for preventing or improving decline in brain function
ES2458353T3 (es) Preparación que comprende aminoácidos y plantas y su actividad en la destoxificación de alcohol y en el tratamiento de la migraña
JP5085541B2 (ja) 疲労軽減剤
EP2210601A1 (en) Anti-fatigue agent comprising amino acid composition
JP6193229B2 (ja) 血管内皮機能低下の予防または改善剤
US11654125B2 (en) Agent for elevating nitric oxide concentration
US7932288B2 (en) Composition for relieving subjective symptoms of fatigue
JP5931325B2 (ja) 注意集中力向上剤
AU2013219258A1 (en) Agent for preventing or ameliorating vascular endothelial malfunction
JP2013060406A (ja) 脳疲労改善用経口剤
AU2013339057B2 (en) Agent for preventing or improving decline in brain function
WO2015199203A1 (ja) 眼の疲れ改善剤
JP2021059513A (ja) 網膜色素変性症の治療又は予防のための水性医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181009

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909